Podcasts about year results

Enterprise Ireland Irish medtech client company Aerogen recently announced details of a €300 million transformational scaling and investment plan, which will result in the creation of 725 new jobs in Shannon and Galway over the next 10 years. This announcement was made in conjunction with Enterprise Ireland's End of Year Results for 2024, which confirms that total employment at companies supported by the agency increased to a record 234,454 last year, with 15,741 new jobs created. 64% of the new jobs created in these client companies were located outside the Dublin region, with all nine regions recording jobs growth. To discuss this further, Alan Morrissey was joined by Mid-West Regional Director from Enterprise Ireland, Dan Barry. Photo (C): Aerogen Facebook

Nosipho Radebe is in conversation with Peter Major, a Mining Analyst See omnystudio.com/listener for privacy information.

Nosipho Radebe speaks to Energy Analyst, Tshepo Kgadima See omnystudio.com/listener for privacy information.

Introduction (00:00 - 03:00) Dr. Valentin Fuster introduces the focus of the January 28, 2025, issue of JACC on transcatheter tricuspid valve interventions. He emphasizes the growing importance of addressing symptomatic tricuspid regurgitation, a major predictor of morbidity and mortality, and explores potential treatments that aim to improve quality of life and decrease hospitalizations. Transcatheter Tricuspid Valve Repair (03:00 - 20:30) Fuster discusses two key studies: the TRILUMINATE randomized trial and a large European registry. While the TRILUMINATE trial demonstrated significant quality of life improvements using the TriClip device, it did not show a reduction in mortality or heart failure hospitalizations, suggesting the need for longer follow-up in future studies. Meanwhile, the European registry highlights the effectiveness of the Pascal device, showing significant symptomatic improvements and tricuspid regurgitation reduction in high-risk patients. Transcatheter Tricuspid Valve Replacement (20:30 - 35:00) Fuster moves on to discuss the TRISCEND II pivotal trial on transcatheter tricuspid valve replacement. Like the previous repair methods, it primarily improves health status without significantly reducing mortality or hospitalizations, as shown in the trial's findings. He also mentions an excellent state-of-the-art review on this intervention featured in JACC. Imaging in Transcatheter Valve Interventions (35:00 - 45:00) This section highlights the importance of imaging in transcatheter valve interventions. Fuster presents a new project under the leadership of Dr. Kalyanam Shivkumar, aimed at enhancing cardiac anatomy and function resources, supporting advancements in cardiovascular treatments. Conclusion (45:00 - 55:00) Dr. Valentin Fuster wraps up the podcast by summarizing the key takeaways: while current transcatheter interventions show promise in improving symptoms and quality of life for patients with severe tricuspid regurgitation, long-term follow-up is crucial to fully understand their impact on survival and heart failure hospitalizations.

Introduction (00:00 - 03:00) Dr. Valentin Fuster introduces the focus of the January 28, 2025, issue of JACC on transcatheter tricuspid valve interventions. He emphasizes the growing importance of addressing symptomatic tricuspid regurgitation, a major predictor of morbidity and mortality, and explores potential treatments that aim to improve quality of life and decrease hospitalizations. Transcatheter Tricuspid Valve Repair (03:00 - 20:30) Fuster discusses two key studies: the TRILUMINATE randomized trial and a large European registry. While the TRILUMINATE trial demonstrated significant quality of life improvements using the TriClip device, it did not show a reduction in mortality or heart failure hospitalizations, suggesting the need for longer follow-up in future studies. Meanwhile, the European registry highlights the effectiveness of the Pascal device, showing significant symptomatic improvements and tricuspid regurgitation reduction in high-risk patients. Transcatheter Tricuspid Valve Replacement (20:30 - 35:00) Fuster moves on to discuss the TRISCEND II pivotal trial on transcatheter tricuspid valve replacement. Like the previous repair methods, it primarily improves health status without significantly reducing mortality or hospitalizations, as shown in the trial's findings. He also mentions an excellent state-of-the-art review on this intervention featured in JACC. Imaging in Transcatheter Valve Interventions (35:00 - 45:00) This section highlights the importance of imaging in transcatheter valve interventions. Fuster presents a new project under the leadership of Dr. Kalyanam Shivkumar, aimed at enhancing cardiac anatomy and function resources, supporting advancements in cardiovascular treatments. Conclusion (45:00 - 55:00) Dr. Valentin Fuster wraps up the podcast by summarizing the key takeaways: while current transcatheter interventions show promise in improving symptoms and quality of life for patients with severe tricuspid regurgitation, long-term follow-up is crucial to fully understand their impact on survival and heart failure hospitalizations.

Enterprise Ireland Irish medtech client company Aerogen today announces details of a €300 million transformational scaling and investment plan, which will result in the creation of 725 new jobs in Ireland over the next 10 years. Aerogen is Ireland's largest indigenous medtech company and Enterprise Ireland's largest client company in the sector having firmly established itself as the world leader in acute care aerosol drug delivery. This announcement was made in conjunction with Enterprise Ireland's End of Year Results for 2024, which confirms that total employment at companies supported by the agency increased to a record 234,454 last year, with 15,741 new jobs created. 64% of the new jobs created in these client companies were located outside the Dublin region, with all nine regions recording job growth. Minister for Enterprise, Trade and Employment Peter Burke was on site in Galway to preside over Aerogen's growth announcement and deliver Enterprise Ireland's results. "The government, through Enterprise Ireland, is targeting ambitious scaling of Irish multinationals that will help drive the Irish economy and our competitive advantage forward. Aerogen's announcement today is evidence of that Irish multinational ambition in action, and we are delighted to support them on their patient-focused mission. Commenting on the positive employment growth figures recorded by companies supported by Enterprise Ireland, Minister Burke said, "It is hugely positive to see Enterprise Ireland-supported companies recording job growth for the fourth year in a row. 2024 was a challenging year for some sectors of exporting Irish businesses with high interest rates and international instability impacting business performance, so to record significant employment growth is even more impressive. Today's announcement that Aerogen will implement an ambitious scaling plan, creating high-quality jobs here in the west of Ireland, is very welcome and demonstrates the continued success of Irish companies' performance in export markets. The government stands firm in our commitment to Irish companies competing and growing on a global scale." Aerogen - Transformational Scaling Plan With over 25 years of experience, 300 international patents and over 200 clinical papers, Aerogen technology has been used to treat over 25 million patients in emergency departments, adult and paediatric ICUs, general wards and ambulance services in 75 countries worldwide. Aerogen offers a safe and powerful drug delivery device for the treatment of critical respiratory illness and other non-respiratory illnesses and is the leading manufacturer of high-performance, single-use respiratory nebulisers in the world. The Aerogen Group is headquartered in Dangan, Galway, and the new Irish jobs will be across R&D, manufacturing, science and engineering and located there and at its two manufacturing sites in Parkmore, Galway and in Shannon. The implementation of the transformational scaling plan will enable Aerogen to create up to 725 highly skilled jobs in the West by 2035, increasing its global workforce to over 2,000, of which over 1,100 will be based in Ireland. As part of the ten-year scaling and investment plan, Aerogen aims to accelerate its existing device technology through new product innovation and leveraging of global opportunities. Simultaneously, it will build its emerging biopharmaceutics business with a major breakthrough in treating premature newborns with Infant Respiratory Stress Syndrome. High-quality R&D is crucial to its goal to become a global leader in pulmonary medicine and biopharmaceutical delivery, combined with a true commitment to improving patient care through cutting-edge technologies. Aerogen has been growing at over 20% per annum for the last decade, with annual revenues now over €150 million, and has contributed €130 million to local Irish businesses in that time. Over the next five years Aerogen expects to contribute a further €250 million in income and...

In this episode, Dr. Valentin Fuster discusses the five-year results of the SOFT TAVI trial, which compared self-expanding and balloon-expanding valves for transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis. The findings reveal similar long-term outcomes for both valve types and anesthesia strategies, with subtle differences in stroke rates and pacemaker implantations, emphasizing the growing safety and efficacy of conscious sedation in TAVR procedures.

Old Saint Dick, Employee of the Year Results, Morgan Vacation Update and more!

Begbies Traynor Executive Chairman, Ric Traynor and Group Finance Director, Nick Taylor present the group's results for the six months ended 31 October 2024, followed by Q&A. Ric Traynor, Executive Chairman 00:16 - Introduction 01:05 - H1 highlights Nick Taylor, Group Finance Director 03:04 - H1 financial highlights 06:45 - Reconciliation of adjusted EBITDA to statutory profit 07:38 - Financial position 11:02 - Financial summary & outlook Ric Traynor, Executive Chairman 12:22 - Insolvency levels 14:08 - Property market transaction levels 15:23 - Divisional growth 17:24 - Case studies 18:25 - Organic growth 19:58 - Growth strategy 20:43 - Growth in property advisory 21:33 - Historic performance 22:06 - Summary & outlook 22:48 - Q&A Begbies Traynor Group plc is a leading UK advisory firm with expertise in business recovery, advisory and corporate finance, valuations, asset sales and property consultancy. We have 1,300 colleagues operating from 45 locations across the UK, together with four offshore offices. Our multidisciplinary professional teams include insolvency practitioners, accountants, lawyers, funding professionals and chartered surveyors. Business recovery Corporate and personal insolvency; contentious insolvency; creditor services Advisory and corporate finance Debt advisory and finance broking; corporate finance; special situations M&A; financial advisory Valuations Property, business and asset valuations Asset sales Property, plant and machinery auctions; property and business sales agency Property consultancy Building consultancy; transport planning; commercial property management; insurance and protection Further information can be accessed via the group's website at https://ir.begbies-traynorgroup.com/.

MindGym CEO, Christoffer Ellehuus and CFO, Emily Fyffe present the group's results for the six months ended 30 September 2024. Christoffer Ellehuus, CEO 00:16 - Introduction 04:04 - Market opportunity & dynamics Emily Fyffe, CFO 07:11 - HY FY25 financial highlights Christoffer Ellehuus, CEO 10:00 - Global energy framework case study 12:15 - Finastra case study 14:33 - Vision for growth 15:50 - Packaged solutions 17:43 - Technology platform partnerships 18:56 - New product launches 22:01 - Diagnostics & analytics products 26:16 - Summary & outlook MindGym is a company that delivers business improvement solutions using scalable, proprietary products which are based on behavioural science. The Group operates in three global markets: business transformation, human capital management and learning & development. MindGym is listed on the London Stock Exchange Alternative Investment Market (ticker: MIND) and headquartered in London. The business has offices in London, New York and Singapore. Further information is available at www.themindgym.com

DSW Capital CEO, James Dow, CEO Designate, Shru Morris and CFO & COO, Pete Fendall present the group's results for the six-month period ended 30 September 2024, followed by Q&A. James Dow, CEO 00:16 - Introduction 01:39 - H1 FY25 highlights 03:15 - The DSW licence model 05:47 - Current service lines Pete Fendall, CFO & COO 06:25 - H1 FY25 financial highlights 08:48 - Income statement 10:21 - Balance sheet 11:08 - Cashflow 12:01 - Network KPI's 14:15 - Recriutment Shru Morris, CEO designate 15:51 - Growth opportunities 18:39 - Acquisition of DR Solicitors Limited James Dow, CEO 21:45 - Management changes 23:19 - Summary & Outlook 26:17 - Q&A DSW Capital, owner of the Dow Schofield Watts and DR Solicitors brands, is a profitable, mid-market, challenger professional services network with a cash generative business model and scalable platform for growth. Originally established in 2002, by three KPMG alumni, Dow Schofield Watts is one of the first platform models disrupting the traditional model of accounting professional services firms. DSW Capital operates licensing arrangements with its businesses and has over 130 fee earners across 12 offices in the UK. These businesses trade primarily under the Dow Schofield Watts and DR Solicitors brands. DSW Capital's vision is for our brands to become the most sought-after destinations for ambitious, entrepreneurial professionals to start and develop their own businesses. Through a licensing model, DSW Capital gives professionals the autonomy and flexibility to fulfil their potential. Being part of the DSW Capital group brings support benefits in recruitment, funding and infrastructure. DSW Capital's challenger model attracts experienced, senior professionals, predominantly with a "Big 4" accounting firm or "Magic Circle" legal background, who want to launch their own businesses and recognise the value of DSW Capital's brands and the synergies which come from being part of the network. DSW Capital aims to scale its agile model through organic growth, geographical expansion, additional service lines and acquisitions. The Directors are targeting high margin, complementary, niche service lines with a strong synergistic fit with the existing network.

Sosandar Co-CEOs, Julie Lavington and Ali Hall, and CFO, Steve Dilks, present the company's results for the six months ended 30 September 2024, followed by Q&A. Julie Lavington, Co-CEO 00:16 - Introduction 00:56 - H1 highlights Steve Dilks, CFO 02:17 - H2 Outlook Ali Hall & Julie Lavington, Co-CEOs 03:58 - Store rollout 05:33 - Halo effect of stores 07:19 - First 10 weeks since opening Steve Dilks, CFO 08:06 - Increasing margin 10:26 - H1 FY25 Financial highlights 11:27 - Income statement 12:34 - Balance sheet 13:32 - Cashflow Ali Hall & Julie Lavington, Co-CEOs 14:28 - Product sucess 15:19 - New product categories 16:13 - Next homeware licencing partnership 17:17 - Summary & Outlook 18:19 - Q&A Sosandar is a women's fashion brand in the UK targeting style conscious women who have graduated from lower quality, price-led alternatives. The Company offers this underserved audience fashion-forward, affordable, quality clothing to make them feel sexy, feminine, and chic. The business sells predominantly own-label exclusive product designed and tested in-house. Sosandar's product range is diverse, providing its customers with an array of choice for all occasions across all women's fashion categories. The company sells through Sosandar.com and its own stores, and has a number of high value brand partnerships including with NEXT and Marks & Spencer. Sosandar's success has been built on an exceptional product range, seamless customer experience and impactful, lifestyle marketing, all of which is underpinned by combining innovation with data analysis. Our growth strategy is focused on continuing to grow brand awareness and expand our addressable market and routes to market, reaching customers wherever they wish to shop. This is achieved both through direct to consumer channels and through chosen third-party partners. Sosandar was founded in 2016 and listed on AIM in 2017. More information is available at www.sosandar-ir.com

Join our hosts Can Gollmann-Tepeköylü and Miia L Lehtinen for their late-breaking trials highlights presented at the 38th EACTS Annual Meeting in Lisbon, including: (0:39 - 4:31) Long-term mortality after PCI or CABG in patients with diabetes and multivessel coronary artery disease: A SWEDEHEART study by Dr Emma C Hansson (4:32 - 8:33) Long-term (>10 years) results of transcatheter Mitral valve-in-valve implantation for degenerated surgical mitral bioprosthesis: Italian MItral VIV registry (MIVIV registry) by Dr Edoardo Zancanaro  (8:34 - 11:55) Personalized multimodal teleprehabilitation in elective cardiac surgery: results from the Digital Cardiac Counselling multicentered randomized Controlled Trial (ClinicalTrials.gov number, NCT04393636.) by Dr Bart Scheenstra   (11:55 - 16:15) 5-Year Results on Aortic Remodeling in the Dissected Aorta Repair Through Stent (DARTS) Implantation Trial by Dr Ryaan EL-Andari (16:16 - 19:49) Clinical impact of continuous postoperative pericardial flushing on bleeding-related complications after cardiac surgery by Dr Robert Klautz

Mirza Umair Khalid, MD, social media editor of JACC: Cardiovascular Interventions, and Thomas J. Stocker, MD, discuss a recently published original research paper reporting the long-term outcomes after mitral transcatheter edge-to-edge repair for secondary mitral regurgitation.

JACC Deputy Editor Erica S. Spatz, MD, FACC, joins author Rishi Wadhera, MD, to discuss his paper on rural and urban differences in cardiovascular mortality in the United States, and the impact of the COVID-19 pandemic.

Nick and Harrison talk all things baseball. This week, we discuss the shocking Rookie of the Year results, the All MLB teams, Silver Sluggers, the latest free agency rumors, news around the league, and some trivia.

In this episode of JACC, Author Suzanne Arnold, MD and JACC Associate Editor Dennis T. Ko, MD, discusses groundbreaking findings from the Tricatin-2 trial, the first clinical study on transcatheter tricuspid valve replacement. The results reveal significant improvements in quality of life for patients, particularly those with severe tricuspid regurgitation, highlighting the transformative potential of this procedure compared to traditional medical therapy.

Stephen Grootes talks to Pick n Pay CEO Sean Summers about the retail group's interim results, which saw a R827.4 million loss despite 3.7% turnover growth.See omnystudio.com/listener for privacy information.

Author Joerg Hausleiter, MD and Executive Associate Editor Aakriti Gupta, MD, FACC. discuss the TAVR UNLOAD trial, which focused on patients with moderate aortic stenosis (AS) and reduced ejection fraction (HFrEF). The trial found no significant difference in the primary endpoint (composite of mortality, stroke, and hospitalizations) between the TAVR and clinical surveillance groups. However, patients who underwent TAVR showed a significant improvement in quality of life at one year. The conversation highlighted the need for individualized treatment approaches, emphasizing patient selection, while also considering trial limitations, including slow enrollment and study size.

Eneraqua Technologies CEO, Mitesh Dhanak and Interim CFO, James Lamb present the group's results for the six months ended 31 July 2024, followed by Q&A. Mitesh Dhanak, CEO 00:16 - Introduction 01:49 - HY 2025 Operational highlights James Lamb, Interim CFO 05:21 - Income statement 06:27 - Balance sheet 07:27 - Net debt bridge Mitesh Dhanak, CEO 08:27 - Orderbook 10:27 - Solutions 12:23 - Technology IP 13:58 - Addressable market 16:34 - Growth strategy 18:00 - Case studies 20:58 - Outlook 22:52 - Q&A Eneraqua Technologies (AIM:ETP) is a specialist in energy and water efficiency. The Group has two divisions energy and water. Energy is the larger division, with the Company focused on clients with end of life gas, oil or electric heating and hot water systems. The Group provides turnkey retrofit district or communal heating systems based either on high-efficiency gas or ground/air source heat pump solutions that support Net Zero and decarbonisation goals. The water division is a growing service offering focused on water efficiency upgrades for utilities and commercial clients including hotels and care homes. The activities in both divisions are underpinned by the Company's wholly-owned intellectual property, the Control Flow HL2024 family of products which reduce water wastage and improve the performance of heating and hot water systems. The Company's main country of operation is the United Kingdom. The Company's head office is based in London with additional offices in Leeds, Washington (Sunderland), India, Spain and the Netherlands. The Company has 168 employees, with the majority employed within the UK. Eneraqua Technologies has received the London Stock Exchange's Green Economy Mark. To find out more, please visit: www.eneraquatechnologies.com

Mitesh Dhanak, CEO gives an overview of the interim results for the six months ended 31 July 2024. 00:25 Results highlights 01:24 Financial performance 02:18 Strategic and operational highlights 03:55 Outlook Eneraqua Technologies plc (AIM:ETP) is a specialist in energy and water efficiency. The Group has two divisions energy and water. Energy is the larger division, with the Company focused on clients with end of life gas, oil or electric heating and hot water systems. The Group provides turnkey retrofit district or communal heating systems based either on high-efficiency gas or ground/air source heat pump solutions that support Net Zero and decarbonisation goals. The water division is a growing service offering focused on water efficiency upgrades for utilities and commercial clients including hotels and care homes. The activities in both divisions are underpinned by the Company's wholly-owned intellectual property, the Control Flow HL2024 family of products which reduce water wastage and improve the performance of heating and hot water systems. The Company's main country of operation is the United Kingdom. The Company's head office is based in London with additional offices in Leeds, Washington (Sunderland), India, Spain and the Netherlands. The Company has 168 employees, with the majority employed within the UK. Eneraqua Technologies has received the London Stock Exchange's Green Economy Mark. www.eneraquatechnologies.com

The Pebble Group CEO, Chris Lee and CFO, Claire Thomson present the group's results for the six months ended 30 June 2024, followed by Q&A. Chris Lee, CEO 00:16 - Introduction 01:19 - Market Opportunity 02:33 - Investment case 03:37 - HY24 highlights Claire Thomson, CFO 04:52 - HY24 financial highlights 05:25 - Key financial dynamics 05:56 - Income statement 06:15 - Balance sheet 06:43 - Cash flow 07:13 - Use of capital Chris Lee, CEO 08:26 - Facilis Group performance Claire Thomson, CFO 15:45 - Brand addition performance Chris Lee, CEO 18:16 - ESG 20:09 - Summary & Outlook 21:12 - Q&A The Pebble Group is a provider of digital commerce, products and related services to the global promotional products industry, comprising two differentiated businesses, Facilisgroup and Brand Addition, focused on specific areas of the promotional products market. For further information, please visit www.thepebblegroup.com.

Itaconix CEO John Shaw joined Steve Darling from Proactive to provide an update on the company's recent performance and initiatives, with a particular focus on its evolving digital marketing strategy. Shaw expressed optimism about Itaconix's trajectory, reflecting on both the successes and challenges faced in the first half of 2024. He noted that while the company's restructuring efforts resulted in lower revenues, they successfully improved gross profit margins, which are now nearing their target of over 35%. Shaw emphasized that Itaconix is prioritizing profitability by leveraging its unique, high-value ingredients used in everyday consumer products such as detergents and deodorants. He also unveiled a new corporate website aimed at attracting brand managers by offering specific value propositions, which will facilitate faster and more efficient product launches. Shaw explained, “Our digital marketing initiative allows us to target very specific audiences with tailored value propositions, speeding up engagement and adoption.” As Itaconix enters the second half of 2024, digital marketing will remain a key component in driving growth, expanding the company's reach, and capitalizing on new market opportunities. #proactiveinvestors #itaconixplc #aim #itx #otcqb #itxxf #DigitalMarketing #ConsumerProducts #Sustainability #Profitability #GrossMargin #BrandManagers #InnovativeIngredients #ProactiveInvestors #CorporateStrategy#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Welcome to The LA Poker Roundup! The place for recent news and events in the LA poker community, with a focus on tournaments. This show will go over events happening the following week, the pros and cons of different events along with the opinions of your hosts on the hottest topics in the poker world. Tune in Tuesday nights to talk LA poker with us! Subscribe and turn on notifications so you don't miss a single Roundup! This week: 00:00 Starting soon 00:56 Intro 03:19 Results from Commerce and the Bike! 10:28 Derek's deep run in the Mega Millions 17:02 Tragedy this weekend at the Bike! 19:33 Ty's thoughts on the Hold 'em Series so far 35:35 Updated Player of the Year Results! 41:10 Ari Engel article on Smaller bubbles, Transparency in Rake 51:00 EPT Barcelona rules and procedure changes 56:51 Haliey Welch on CPT Invitational 1:00:55 Controversy over Abby Merk video 1:06:34 Gardens Fall Schedule out 1:11:13 Weekly Roundup Follow us on Twitter and Instagram Ty's Twitter: https://twitter.com/TyDobbertin Ty's Instagram: https://www.instagram.com/tydobbertin/ Derek's Twitter: https://twitter.com/kwansfull Derek's YouTube: https://www.youtube.com/@kwansfull Derek's Instagram: https://www.instagram.com/kwansfull/​

FGX HY2024 Half Year Results Q&A Webinar by Wilson Asset Management

FGG HY2024 Half Year Results Q&A Webinar by Wilson Asset Management

What do the Seahawks need to do this season to have success and find the postseason? If this defense could be league average and mid-tier in the running game, this team should find success // Need to Know: The Mariners lose on the road to the LA Angels and the Mariners are slowly started to run out of chances to get to the postseason. We are now officially in Week 1 of the NFL season, the Seahawks take on the Broncos on Sunday. College Football is in full swing as the UW Huskies took down Weber State 35-3. // Bryan Woo and Bryce Miller had okay outings against the Angels over the weekend but were not able to secure the wins. These two pitchers had fantastic ERA’s and innings pitched, they are having great second halves of the season and are performing extremely well this year as they did at this time last season. Of the starting 5 for this Mariners p[itching staff, Woo is the most unique and has less walks than George Kirby with 2.5 walks per nine innings. // Blue 88 Baseball Edition: What will happen with the AL Wild Card race, are the Red Sox and Tigers teams that will keep the Mariners out? Who is a better player: Aaron Judge or Shohei Ohtani? Aaron Judge is accomplishing feats that nobody has done in decades. Ohtani could have a 50/50 season which has never happened before. Why is there not one dominant team in the MLB this season?

Noluthando Mthonti-Mlambo speaks to Gugu Mthethwa, Group Chief Operations Officer at Santam See omnystudio.com/listener for privacy information.

Air New Zealand's financial results are out tomorrow - and hopes aren't flying particularly high.  The airline has been hit with plane engine troubles, increased competition and decreased consumer demand. Milford Asset Management's Jeremy Hutton outlined some predictions about the airline's financial state. LISTEN ABOVESee omnystudio.com/listener for privacy information.

Impact of Valve Type and Anesthesia Strategy for TAVI ? 5-Year Results of the SOLVE-TAVI Trial

Jason Quinn, Nedbank Group executive takes Stephen Grootes through the lender's half-year results.  Nedbank has upped its interim dividend by 11.5% after headline earnings rose 8% to R7.91 billion in the six months to end-June.See omnystudio.com/listener for privacy information.

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

What is the Portfolio Waterfall? With it, can you really get a SAFE 6% withdrawal rate in retirement? Is the 4% rule dead in light of this new, revolutionary, strategy? 00:00 - Intro 00:39 - Brainstorming with Bears, Honey, and Helicopters 06:12 - Portfolio Waterfall Explained 13:21 - Results of My Portfolio Waterfall Study - (20 years) 15:07 - What's the Tradeoff?? 17:17 - 30 Year Results 18:15 - 40 Year Results 18:55 - 50 Year Results 19:27 - Characterizing the Portfolio Waterfall 20:15 - 60 Year Results 21:03 - Ending Nest Egg Value Tradeoff Abated! 21:37 - My Thoughts on These Results 22:13 - Assumptions for My Proof of Concept Model 23:01 - Historical Data 27:40 - Simulated Data  35:41 - Portfolio Waterfall Website - https://portfoliowaterfall.com/ 36:27 - Closing Thoughts Today's episode covers a very new and revolutionary topic that applies some NEW ideas. For this reason, in today's story, Jay shares a how some seemingly silly brainstorming resulted in a real solution to power outages in Alaska. This story involves bears, honey, and helicopters. The lesson here in is how real solutions and progress can benefit from open-minded efforts to think critically even when an idea seems pretty out there. The main topic explains a revolutionary new retirement distribution strategy - the Portfolio Waterfall! This is the brain child of the financial adviser, Josh Curtis. These results are ASTOUNDING! Can this strategy actually DOUBLE your income in retirement? Is the 4% rule history? Be sure to listen all the way through to fully understand the assumptions of this model. The simulated results required a new method of modeling fully unique to our work here at HopeFilled Financial Coaching. We welcome your comments and questions on this topic. We are sincerely excited to share this exciting strategy with you. For more background on this strategy check out these videos: Mutual Funds Uncovered: https://youtu.be/TJGnWQMMtAA  New Retirement Study: https://youtu.be/I8TFUMUnG3E How to Never Run Out of Money: https://youtu.be/NDYPoIBeX0A Kicking the Bucket Retirement Strategy: https://youtu.be/JDfOsfrIhFs Viral 8% Dave Ramsey Call Episode: https://www.youtube.com/watch?v=BugfOEGzG0Y Note: I mentioned in this episode that the latest study I completed for comparison is from January. This study and the above episode on it were published in March of this year even though the work on the model started in January. Please don't forget to like, share, and subscribe! Doing so helps us grow and share HopeFilled financial wisdom. We release a new episode every Tuesday! Subscribe if you don't ever want to miss an episode! You can submit a question on our website (hopefilledfinancial.com) or message us on Facebook (@HopeFilledFinancial). Disclaimer: This podcast serves as educational entertainment only. Any and all opinions relating to real estate, law, taxes, insurance, and/or securities investing that may be contained within this podcast should not be interpreted or implemented as recommendations nor advice. The opinions related to these topics – especially those regulated by state and/or federal entities – should never be taken as replacement for advice from a competent, licensed professional. HopeFilled Financial Coaching is not liable for any individual acting on any understanding of topics directly or indirectly related to real estate, legal practice, taxes, insurance, or investing even if an individual in question changed their understanding after listening to this podcast. All listeners are entirely responsible for seeking advice from licensed professionals before taking any action of their own. Our Website: HopeFilledFinancial.com Music: "Take Me Higher" by Jahzzar Music Copyright License: This music is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Doctors told Erica her hip pain was from hip dysplasia and a hip labral tear. Her hip pain got so bad she had to walk with a cane. The surgery to fix hip dysplasia sounded brutal, so she tried to heal her hip pain without surgery. This is her story of recovery from hip pain, a hip labral tear, and hip dysplasia. Watch on YT: https://youtu.be/JgOqnRhJkKM HELPFUL LINKSIn-depth Article on Hip Dysplasia: https://www.uprighthealth.com/blog/dysplasia30 Year Results for Patients of Periacetabular Osteotomy Surgeries: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339143/Exercises to Help Your Hip Pain: https://www.youtube.com/watch?v=YqLchqRnUS0Strengthen Your Hip Flexors: https://youtu.be/OcYulyMRdys?si=XIxAtOgTyh0FUSXP SUPPORT THE MISSION AND YOURSELF

Michael J. Reardon and C. Michael Gibson discuss the trial's 4-year results in low-surgical-risk patients with severe aortic stenosis randomized to self-expanding TAVI or SAVR.

Dark energy is a mysterious force that is causing the expansion of the universe to accelerate. The Dark Energy Spectroscopic Instrument (DESI) attached to the Nicholas U. Mayall Telescope at Kitt Peak National Observatory is currently measuring the redshifts to tens of millions of galaxies to help unravel the mystery of dark energy. In this podcast, NOIRLab's Dr. Stephanie Juneau talks about the results from the first year of observations with DESI.   Bios:  Rob Sparks is in the Communications, Education and Engagement group at NSF's NOIRLab in Tucson, Arizona. Dr. Stephanie Juneau is an astronomer at NSF NOIRLab, and a data scientist for the Astro Data Lab. She obtained her BSc and MSc in physics from the Université de Montréal, and her PhD from the University of Arizona in 2011. She then moved to CEA-Saclay in France, where she started as a Marie Curie fellow before becoming staff researcher in 2012. She moved back to Tucson, Arizona in 2016 to join the scientific staff at NSF NOIRLab.   Dr. Juneau's expertise lies primarily in the field of supermassive black hole and galaxy evolution. She is interested in answering questions about the growth of galaxies and that of the black holes that reside in their centers, as well as the interplay between the two. Her work brings together multiwavelength observations, close comparison with numerical simulations, and ranges from detailed case studies to statistical analysis of large datasets. As a member of the DESI and Euclid collaborations, she is particularly excited about leveraging millions of galaxy and quasar spectra to further our understanding of the black hole-galaxy connection and expand to larger scales.   Links: NOIRLab Press Release: https://noirlab.edu/public/news/noirlab2408/ NOIRLab social media channels can be found at: https://www.facebook.com/NOIRLabAstro https://twitter.com/NOIRLabAstro https://www.instagram.com/noirlabastro/ https://www.youtube.com/noirlabastro   We've added a new way to donate to 365 Days of Astronomy to support editing, hosting, and production costs.  Just visit: https://www.patreon.com/365DaysOfAstronomy and donate as much as you can! Share the podcast with your friends and send the Patreon link to them too!  Every bit helps! Thank you! ------------------------------------ Do go visit http://www.redbubble.com/people/CosmoQuestX/shop for cool Astronomy Cast and CosmoQuest t-shirts, coffee mugs and other awesomeness! http://cosmoquest.org/Donate This show is made possible through your donations.  Thank you! (Haven't donated? It's not too late! Just click!) ------------------------------------ The 365 Days of Astronomy Podcast is produced by the Planetary Science Institute. http://www.psi.edu Visit us on the web at 365DaysOfAstronomy.org or email us at info@365DaysOfAstronomy.org.

#84 - The Charles Episode (Draft Year). Recorded at 8:00 PM CDT on Wednesday, May 15th, 2024. Timestamps: NBAonTNT (0:00). Nuggets-Wolves (16:20). Celtics-Cavs + Has Jokić Shown This Before? (46:13). Knicks-Pacers (1:23:40). Mavs-Thunder (1:41:35). Coach of the Year & Exec. of the Year Results (1:47:19). Links: Patreon: patreon.com/hooptheory | Buy Me A Coffee: https://www.buymeacoffee.com/HoopTheory | YouTube: https://www.youtube.com/channel/UCWgCLIJJEDng1EAVIFb8O1A | TikTok: https://www.tiktok.com/@hoop_theory?is_from_webapp=1&sender_device=pc | Twitter: https://twitter.com/HoopTheory_Pod | Instagram: https://www.instagram.com/hoop.theory_pod/ | Facebook: https://www.facebook.com/lojowo17/reels/ | Spotify: http://open.spotify.com/show/5hR9hfjbn | Apple Podcasts: http://podcasts.apple.com/us/podcast/the

Mutations in PDE6B are a leading cause of retinitis pigmentosa.

Adrian Gore, Founder & Group CEO Officer of Discovery takes Ray White through the company's half-year results.See omnystudio.com/listener for privacy information.

Unlike traditional pain management, ReActiv8 therapy uniquely addresses chronic low back pain by restoring neuromuscular control and functional spine stability. In this episode, Dr. Chris Gilligan, MD, MBA, Executive Medical Director, Mass General Brigham Global Advisory, Senior Medical Director of Periprocedural Services, Director of Brigham and Women's Spine Service Line, Chief - Division of Pain Medicine, Brigham and Women's Hospital, discusses the groundbreaking five-year data on ReActiv8 therapy for chronic low back pain, offering insights into this transformative approach and its impact on patients' lives. Chris delves into the significant findings from his research, shedding light on the ReActiv8 therapy's effectiveness in addressing chronic low back pain and improving patients' quality of life. He provides an in-depth overview of the research, covering the methodology, patient demographics, and the remarkable outcomes achieved over the five-year study period. Dr. Gilligan also addresses the implications of the findings for payers, providers, and patients, offering a holistic perspective on the therapy's clinical and economic significance. Join Chris and Saul as they uncover the remarkable impact of this novel therapy and explore its broader implications for patients, physicians, and payers in the healthcare ecosystem. Resources:  Watch this amazing interview here. Connect with and follow Chris Gilligan on LinkedIn here. Learn more about ReActiv8-B Trial 3-Year Patient Outcomes Data here. Listen to Dr. Chris's previous interview. Visit the Mainstay website here.

In this episode of the BackTable Podcast, host Dr. Sabeen Dhand interviews Dr. Eric Secemsky about the efficacy of drug eluting technologies in vascular interventions, with Dr. Secemsky offering insight into his own practice. Dr. Secemsky is an interventional cardiologist practicing at Beth Israel Deaconess Medical Center in Boston. Dr. Secemsky believes that drug coated technology is a game-changer in the endovascular space since it improves patient outcomes by reducing the risk of needing additional procedures. Dr. Secemsky highlights the importance of various trials such as IMPERIAL and EMINENT, which compare the effectiveness of different stents. He also speaks about the significance of the Cook Medical prediction model to calculate intervention success rates and the role of disease site-specific interventions. Dr. Secemsky ends the podcast by sharing his thoughts about advancements in the near future, including the use of bioabsorbable stents and sirolimus drug-coated balloons. --- CHECK OUT OUR SPONSOR Cook Medical Zilver PTX https://www.cookmedical.com/peripheral-intervention/zilver-ptx/ --- SHOW NOTES 00:00 - Introduction 09:31 - Understanding Drug Coated Balloons and Stents 14:29 - The Paclitaxel Controversy 19:30 - Stenting Algorithm for Fem-Pop Disease 23:55 - Impact of Lithotripsy on Drug Delivery 26:02 - Predictability Models for Revascularization 29:14 - Economic Considerations in Drug Eluting Stent Usage 31:33 - Highlighting Trials on Drug Coated Technology and Drug Eluting Stents 37:08 - Future Technologies: Drug on Stent Grafts and Spot Stenting --- RESOURCES Zilver PTX Cook Prediction Model: https://cooksfa.z13.web.core.windows.net/ Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials: https://www.ahajournals.org/doi/full/10.1161/JAHA.118.011245 Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial: https://pubmed.ncbi.nlm.nih.gov/26969758/ Mortality in randomized controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02189-X/fulltext Outcomes of Stented vs Nonstented Femoropopliteal Lesions Treated With Drug-Coated Balloon Angioplasty: https://pubmed.ncbi.nlm.nih.gov/35179065/ Drug coated balloon improves outcomes of sub-optimal Supera deployment in the intermediate term: https://pubmed.ncbi.nlm.nih.gov/36494491/ Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study: https://pubmed.ncbi.nlm.nih.gov/28916599/ Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial: https://pubmed.ncbi.nlm.nih.gov/34167675/ Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial: https://pubmed.ncbi.nlm.nih.gov/36254728/ A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomized, non-inferiority trial: https://doi.org/10.1016/S0140-6736(18)32262-1 SPORTS Clinical Trial Results Boston Scientific: https://www.bostonscientific.com/en-EU/medical-specialties/vascular-surgery/drug-eluting-stent-drug-coated-balloon/eluvia/sports-rct.html

We discuss a comparative trial of preventive therapy for non-proliferative retinopathy vs. ad hoc treatment of disease complications with Dr. Hani Salehi-Had of Retina Associates of Southern California, Huntington Beach, California.

The U.S. economy added a solid number of jobs, the unemployment rate held steady, and a lot of people got raises. But, today we ask whether fewer temporary workers could mean recession, and whether higher wages might cause interest rates to stay high. Related episodes:The Indicator of the Year (Apple / Spotify) Predicting next year's economic storylines (Apple / Spotify) The money illusion For sponsor-free episodes of The Indicator from Planet Money, subscribe to Planet Money+ via Apple Podcasts or at plus.npr.org. Music by Drop Electric. Find us: TikTok, Instagram, Facebook, Newsletter.

Commentary by Dr. Valentin Fuster

Welcome to Her Ambitious Career, the personal branding and success podcast for corporate women who want to get promoted, be sought out for their expertise and be paid appropriately for their impact.Hi there! I'm Rebecca Allen and I am a Executive & Personal Brand Coach who is all about celebrating your wins and helping you learn as you get there.As 2023 draws to a close I really wanted to give you an insight into some of our results at Illuminate Personal Growth... and give you a sneak peek behind the scenes of what's been happening! Every year, I work with between 40 and 50 women on a 1:1 basis... which doesn't include the fabulous ladies in our Thought Leaders Masterclass groups or our Inner Circle memberships... It's a busy, busy world at Illuminate!And within those 1:1 clients these last 12 months...80%+ were promoted or landed new internal roles40%+ successfully negotiated pay rises or improved financial packagesAlmost all of my clients reported:A positive shift in perception that key stakeholders had of themAnd a shift in confidence in  I don't know about you - but those results are something to be proud of!Here's something interesting I said in this ep! :)"The shift in confidence that so many of my clients experience is profound. You get out of your own way, stop overthinking or second guessing yourself  and start focusing instead on clarity, objectivity and self-assuredness - would that be liberating outcome for you? To get rid of all that baggage?"  (Rebecca Allen, Career Success Coach and host of Her Ambitious Career podcast)*****Some More About Your Host:Rebecca Allen is a Career Success Coach for ambitious women who want more from their lives and careers. She has worked over the last 13+ years with clients from companies including ANZ Bank, Origin Energy, J.P. Morgan, PwC, McKinsey, IHS Markit and Coca-Cola Amatil and loves getting those excited phone calls from clients saying they've been promoted, have negotiated a seismic pay rise or have moved into a role completely aligned with their mission, values and strengths.Her own ambitions include raising two beautiful, happy confident children; building a fun and impactful coaching business that empowers 50,000 women worldwide; and visiting Alaska!******3 FREE Ways Rebecca Can Help You Get Promoted this Year: 1. Get a copy of Rebecca's free download, Land Your Next Promotion Checklist  - Click here2. Read more from Rebecca's blog - Click here3.  Listen to more eps from this podcast - Click hereRead more about the Personal Brand Project (our entry level program within our Inner Circle) right here.Connect with Rebecca:LinkedinInstagramfb group

JNIS Editor-in-Chief, Dr. Felipe C. Albuquerque, is joined from New York by Prof. David Fiorella (1) to discuss the paper, "Safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide necked bifurcation aneurysms: final 5 year results of the pivotal WEB Intra-saccular Therapy study (WEB-IT)". Prof. Fiorella explains the results of this extensive study across 27 locations, with the WEB device proving to be a durably effective and safe endovascular treatment option for wide-necked bifurcation aneurysms. Read the paper: https://jnis.bmj.com/content/15/12/1175  (1) Department of Neurosurgery, State University of New York at Stony Brook, Stony Brook, New York, USA Please subscribe to the JNIS Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest episodes. Also, please consider leaving us a review or a comment on the JNIS Podcast iTunes page: https://podcasts.apple.com/gb/podcast/jnis-podcast/id942473767  Thank you for listening! This episode was produced and edited by Brian O'Toole. 

Polymer-Free Amphilimus-Eluting Stents vs. Biodegradable-Polymer Everolimus-Eluting Stents in All-Comers Undergoing PCI: 1-Year Results of the PARTHENOPE Trial

Brandon Hyde and Skip Schumaker won the Manager of Year Awards. Before you wonder where Bruce Bochy is, remember that these are awards for the Regular Season.Meanwhile, Paul Holden of Locked on Rockies stops by to wonder if the Rox will be the next team to jump from 100 losses to the World Series in two years.Follow Paul on Twitter @paulholden33Support Us By Supporting Our Sponsors!Jase MedicalGet $20 off these lifesaving antibiotics with Jase Medical by using code LOCKEDON at checkout on jasemedical.com.FanDuelScore early this NFL season with FanDuel, America's Number One Sportsbook! Right now, NEW customers get ONE HUNDRED AND FIFTY DOLLARS in BONUS BETS with any winning FIVE DOLLAR MONEYLINE BET! That's A HUNDRED AND FIFTY BUCKS – if your team wins! Visit FanDuel.com/LOCKEDON to get started.FANDUEL DISCLAIMER: 21+ in select states. First online real money wager only. Bonus issued as nonwithdrawable free bets that expires in 14 days. Restrictions apply. See terms at sportsbook.fanduel.com. Gambling Problem? Call 1-800-GAMBLER or visit FanDuel.com/RG (CO, IA, MD, MI, NJ, PA, IL, VA, WV), 1-800-NEXT-STEP or text NEXTSTEP to 53342 (AZ), 1-888-789-7777 or visit ccpg.org/chat (CT), 1-800-9-WITH-IT (IN), 1-800-522-4700 (WY, KS) or visit ksgamblinghelp.com (KS), 1-877-770-STOP (LA), 1-877-8-HOPENY or text HOPENY (467369) (NY), TN REDLINE 1-800-889-9789 (TN)Follow & Subscribe on all Podcast platforms…

Brandon Hyde and Skip Schumaker won the Manager of Year Awards. Before you wonder where Bruce Bochy is, remember that these are awards for the Regular Season. Meanwhile, Paul Holden of Locked on Rockies stops by to wonder if the Rox will be the next team to jump from 100 losses to the World Series in two years. Follow Paul on Twitter @paulholden33 Support Us By Supporting Our Sponsors! Jase Medical Get $20 off these lifesaving antibiotics with Jase Medical by using code LOCKEDON at checkout on jasemedical.com. FanDuel Score early this NFL season with FanDuel, America's Number One Sportsbook! Right now, NEW customers get ONE HUNDRED AND FIFTY DOLLARS in BONUS BETS with any winning FIVE DOLLAR MONEYLINE BET! That's A HUNDRED AND FIFTY BUCKS – if your team wins! Visit FanDuel.com/LOCKEDON to get started. FANDUEL DISCLAIMER: 21+ in select states. First online real money wager only. Bonus issued as nonwithdrawable free bets that expires in 14 days. Restrictions apply. See terms at sportsbook.fanduel.com. Gambling Problem? Call 1-800-GAMBLER or visit FanDuel.com/RG (CO, IA, MD, MI, NJ, PA, IL, VA, WV), 1-800-NEXT-STEP or text NEXTSTEP to 53342 (AZ), 1-888-789-7777 or visit ccpg.org/chat (CT), 1-800-9-WITH-IT (IN), 1-800-522-4700 (WY, KS) or visit ksgamblinghelp.com (KS), 1-877-770-STOP (LA), 1-877-8-HOPENY or text HOPENY (467369) (NY), TN REDLINE 1-800-889-9789 (TN) Follow & Subscribe on all Podcast platforms…

The future is bright for the Orioles and D-Backs. Each team is led by their league's 2023 Rookie of the Year winner. Offense was the calling card for each player in 2023. Both Carroll and Henderson are sparkplug atop their respective lineups and can drive the ball out of the yard. Service time manipulation has fallen by the wayside with baseball's new rules. All this (and more) on today's episode.